{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytarabine+%28Phase+1+only%29", "query": { "intervention": "Cytarabine (Phase 1 only)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 127, "total_pages": 13, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytarabine+%28Phase+1+only%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T07:21:48.622Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05712278", "title": "A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukaemia" ], "interventions": [ { "name": "SAR445419", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2023-06-16", "completion_date": "2024-03-12", "has_results": false, "last_update_posted_date": "2026-06-05", "last_synced_at": "2026-09-26T07:21:48.622Z", "location_count": 3, "location_summary": "Omaha, Nebraska • The Bronx, New York • Houston, Texas", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05712278" }, { "nct_id": "NCT00476190", "title": "ALL Adult Consortium Trial: Adult ALL Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Methylprednisone", "type": "DRUG" }, { "name": "Hydrocortisone Sodium Succinate", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "6-MP", "type": "DRUG" }, { "name": "PEG-Asparaginase", "type": "DRUG" }, { "name": "Imatinib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" }, { "name": "E. coli Asparaginase", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 112, "start_date": "2007-04", "completion_date": "2020-03", "has_results": true, "last_update_posted_date": "2025-06-12", "last_synced_at": "2026-09-26T07:21:48.622Z", "location_count": 7, "location_summary": "Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00476190" }, { "nct_id": "NCT06377540", "title": "MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autologous Stem Cell Transplant", "Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Autologous stem cell transplant", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2024-12-04", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-09-26T07:21:48.622Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06377540" }, { "nct_id": "NCT04240002", "title": "A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)" ], "interventions": [ { "name": "gilteritinib", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "granulocyte colony-stimulating factor (G-CSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 9, "start_date": "2020-09-04", "completion_date": "2025-03-17", "has_results": true, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-09-26T07:21:48.622Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04240002" }, { "nct_id": "NCT01035502", "title": "A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Elacytarabine plus idarubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clavis Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2009-12", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-09-27", "last_synced_at": "2026-09-26T07:21:48.622Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01035502" }, { "nct_id": "NCT07153796", "title": "A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Mini-CVD", "type": "DRUG" }, { "name": "MTX/ARA-C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2026-01-30", "completion_date": "2033-09-30", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-26T07:21:48.622Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07153796" }, { "nct_id": "NCT01238211", "title": "Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Core Binding Factor Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Therapy-Related Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2010-12-14", "completion_date": "2021-03-15", "has_results": true, "last_update_posted_date": "2023-03-01", "last_synced_at": "2026-09-26T07:21:48.622Z", "location_count": 65, "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 44 more", "locations": [ { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01238211" }, { "nct_id": "NCT03020030", "title": "Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Lymphoblastic Leukemia, Pediatric" ], "interventions": [ { "name": "Pegaspargase", "type": "DRUG" }, { "name": "Erwinia asparaginase", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "CYTARABINE", "type": "DRUG" }, { "name": "DASATINIB", "type": "DRUG" }, { "name": "DEXAMETHASONE", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "ETOPOSIDE", "type": "DRUG" }, { "name": "HYDROCORTISONE", "type": "DRUG" }, { "name": "LEUCOVORIN CALCIUM", "type": "DRUG" }, { "name": "MERCAPTOPURINE", "type": "DRUG" }, { "name": "METHOTREXATE", "type": "DRUG" }, { "name": "NELARABINE", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 560, "start_date": "2017-03-03", "completion_date": "2034-11", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-26T07:21:48.622Z", "location_count": 7, "location_summary": "Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03020030" }, { "nct_id": "NCT03250338", "title": "Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations" ], "interventions": [ { "name": "Crenolanib", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arog Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 106, "start_date": "2018-08-16", "completion_date": "2026-04-03", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-09-26T07:21:48.622Z", "location_count": 9, "location_summary": "Sacramento, California • Gainesville, Florida • Chicago, Illinois + 4 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03250338" }, { "nct_id": "NCT01147939", "title": "Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Elacytarabine", "type": "DRUG" }, { "name": "Investigator's Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clavis Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 381, "start_date": "2010-06", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-09-27", "last_synced_at": "2026-09-26T07:21:48.622Z", "location_count": 23, "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 16 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147939" } ] }